## IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA CLARKSBURG DIVISION

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

Case No. 1:22-cv-00061-TSK

JURY TRIAL DEMANDED

MYLAN PHARMACEUTICALS INC.,

Defendant.

## **REGENERON'S STIPULATION REGARDING** <u>SUMMARY JUDGMENT AND CASE NARROWING</u>

On April 20, 2023, Mylan moved for summary judgment of certain claims in U.S. Patent Nos. 10,888,601, 11,084,865, 11,253,572 and 11,104,715 (ECF 429).

Subject to all appellate rights, including but not limited to rights of appeal concerning

claim construction, Regeneron does not oppose summary judgment as to the following claims,

under the Court's Claim Construction (ECF 427), on the following bases:

- Regeneron accepts summary judgment of <u>noninfringement</u> of claims 2-3, 6, 12-14, and 16 of U.S. Patent No. 11,104,715.
- Regeneron accepts summary judgment of <u>invalidity</u> of claims 5-6 and 9 of U.S.
  Patent No. 10,888,601.
- Regeneron accepts summary judgment of <u>invalidity</u> of claims 1-5, 8-11, 14, and 26-28 of U.S. Patent No. 11,253,572.

Regeneron opposes summary judgment with respect to all other bases and all other claims that are the subject of Mylan's motion, and will file an opposition to Mylan's motion accordingly.

Case 1:22-cv-00061-TSK-JPM Document 433 Filed 04/27/23 Page 2 of 4 PageID #: 29443

Pursuant to the Court's Scheduling Order (ECF 87), Regeneron hereby narrows these

initial proceedings to the following patents and claims:

- 1. U.S. Patent No. 10,888,601: Claims 11, 19, and 27
- 2. U.S. Patent No. 11,084,865: Claims 4, 7, 9, 11, and 14-18
- 3. U.S. Patent No. 11,253,572: Claims 6, 7, 12, 13, 18, 19, 22, 23, and 25

Date: April 26, 2023

Of Counsel:

David I. Berl (admitted *PHV*) Ellen E. Oberwetter (admitted *PHV*) Thomas S. Fletcher (admitted *PHV*) Andrew V. Trask (admitted *PHV*) Teagan J. Gregory (admitted *PHV*) Shaun P. Mahaffy (admitted *PHV*) Sean M. Douglass (admitted *PHV*) Sean M. Douglass (admitted *PHV*) Kathryn S. Kayali (admitted *PHV*) Arthur J. Argall III (admitted *PHV*) Adam Pan (admitted *PHV*) Nicholas Jordan (admitted *PHV*) Haylee N. Bernal Anderson (admitted *PHV*) Renee M. Griffin (admitted *PHV*) Rebecca Carter (admitted *PHV*)

WILLIAMS & CONNOLLY LLP 680 Maine Avenue, SW Washington, DC 20024 (202) 434-5000 dberl@wc.com eoberwetter@wc.com tfletcher@wc.com atrask@wc.com tgregory@wc.com smahaffy@wc.com sdouglass@wc.com kkayali@wc.com CAREY DOUGLAS KESSLER & RUBY, PLLC

<u>/s/ Steven R. Ruby</u> Steven R. Ruby (WVSB No. 10752) David R. Pogue (WVSB No. 10806) 707 Virginia Street East 901 Chase Tower (25301) P.O. Box 913 Charleston, West Virginia 25323 (304) 345-1234 sruby@cdkrlaw.com drpogue@cdkrlaw.com apan@wc.com njordan@wc.com handerson@wc.com rgriffin@wc.com rebeccacarter@wc.com

Andrew E. Goldsmith (admitted PHV) Evan T. Leo (admitted PHV) Jacob E. Hartman (admitted PHV) Mary Charlotte Y. Carroll (admitted PHV) Sven E. Henningson (admitted PHV)

KELLOG, HANSEN, TODD, FIGEL & FREDERICK, P.L.L.C. 1615 M Street, N.W., Suite 400 Washington, D.C. 20036 TEL: (202) 326-7900 agoldsmith@kellogghansen.com eleo@kellogghansen.com jhartman@kellogghansen.com Mcarroll@kellogghansen.com

Counsel for Plaintiff Regeneron Pharmaceuticals, Inc.

## **CERTIFICATE OF SERVICE**

I hereby certify that on April 26, 2023, the foregoing was served on Mylan's counsel of record via email because the filing function of the Court's CM/ECF system was unavailable. I further certify that on April 27, 2023, after the issue with the CM/ECF system was resolved, the foregoing was electronically filed with the Clerk of the Court via the Court's CM/ECF system, which will serve counsel of record for all parties.

<u>/s/ Steven R. Ruby</u> Steven R. Ruby (WVSB No. 10752)